查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108194

RNA療法與疫苗市場分析及預測（至2035年）：類型、產品類型、技術、組件、應用、製程、最終用戶、解決方案、開發階段

RNA-Based Therapeutics and Vaccines Market Analysis and Forecast to 2035: Type, Product, Technology, Component, Application, Process, End User, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球RNA療法和疫苗市場預計將從2025年的3億美元成長到2035年的20億美元，複合年成長率（CAGR）為24.6%。這一成長主要得益於生物技術的進步、慢性病盛行率的上升、個人化醫療需求的增加以及監管機構對創新療法的支持。 RNA療法和疫苗市場集中度適中，其中mRNA疫苗佔主導地位，其次是RNA干擾療法和反義寡核苷酸。市場需求主要來自感染疾病、腫瘤和遺傳疾病領域的應用，而RNA科學和遞送技術的持續進步也為其提供了支持。競爭格局包括成熟的製藥公司以及新興的生物技術公司，它們透過創新、產品開發和拓展產品線展開競爭。隨著各公司不斷增強研發能力和拓展產品組合，策略聯盟、授權、併購等合作方式仍十分普遍。生技公司、製藥企業和學術機構之間的夥伴關係持續加速下一代RNA療法和疫苗的研發和商業化。

根據類型分類，RNA療法和疫苗市場可分為mRNA療法、siRNA療法、miRNA療法、 RNA干擾（RNAi）、反義RNA和其他療法。其中，mRNA療法憑藉其在疫苗研發方面的成功經驗、快速的設計能力以及在癌症和罕見疾病領域不斷擴大的應用範圍，佔了較大的市場佔有率。 siRNA療法也呈現強勁成長勢頭，這得益於監管部門批准數量的增加以及其選擇性惰性致病基因的能力。同時，隨著研究的深入和臨床管線在多個治療領域的拓展，miRNA療法、反義RNA和RNAi技術也持續受到關注。

市場區隔
種類 基於 mRNA 的療法、基於 siRNA 的療法、基於 miRNA 的療法、 RNA干擾(RNAi)、反義 RNA 等。
產品 RNA疫苗、RNA療法、RNA遞送系統、RNA合成服務等。
科技 體外轉錄、微陣列、RNA定序、 RNA干擾技術等。
成分 RNA分子、遞送載體、穩定劑等。
目的 癌症、感染疾病、遺傳性疾病、心血管疾病、神經系統疾病等。
過程 臨床前研究、臨床試驗、商業化等。
最終用戶 製藥公司、生技公司、研究機構、合約研究組織（CRO）等。
解決方案 治療藥物研發、疫苗研發、藥物傳遞解決方案等。
步 藥物發現、臨床前開發、臨床開發、法規核准及其他

根據應用領域，RNA療法和疫苗市場可細分為癌症、感染疾病、遺傳性疾病、心血管疾病、神經系統疾病及其他領域。其中，感染疾病是主要應用領域，這主要得益於mRNA疫苗的廣泛應用以及對疫情應對的持續投入。癌症也是一個重要的細分市場，這主要得益於個人化RNA免疫療法和治療性疫苗的研發。此外，隨著臨床研究的進展，RNA技術在遺傳性疾病、心血管疾病和神經系統疾病治療的應用日益廣泛，創新的RNA療法在治療這些疾病方面展現出良好的療效和安全性。

區域概覽

北美憑藉著強大的醫藥創新能力、廣泛的生物技術研究以及mRNA技術的成功商業化，在RNA療法和疫苗市場中佔主導地位。領先的生物技術公司、大量的政府資助以及積極的臨床試驗活動正在加速產品開發。該地區還受益於先進的製造能力、有利的監管支援和高額的醫療保健支出。針對腫瘤、罕見疾病和感染疾病的RNA療法研究不斷增加，並持續拓展市場機會。強大的智慧財產權保護和策略夥伴關係進一步鞏固了北美在這一快速發展的治療領域的領先地位。

亞太地區有望成為RNA療法和疫苗市場成長最快的地區，這主要得益於生物技術能力的提升、疫苗生產投資的增加以及政府對先進藥物研發的大力支持。中國、日本、韓國和印度等國正透過公私合營加強RNA技術的研究。對創新療法的需求不斷成長、臨床研究活動的拓展以及製藥生產基礎設施的改善正在推動RNA療法的應用。醫療保健支出的增加以及對疫情防範和精準醫療的日益重視，也進一步促進了該地區市場的強勁成長。

主要趨勢和促進因素

先進RNA平台的擴展正在加速治療領域的創新：

傳訊RNA（mRNA）、小干擾RNA（siRNA）和環狀RNA平台的加速發展是RNA治療和疫苗市場的一大趨勢。脂質奈米顆粒遞送技術和RNA穩定技術的進步正在提高治療效果，並將治療範圍擴展到感染疾病以外的領域。研究人員正積極開發針對癌症、罕見疾病、心血管疾病和自體免疫疾病的RNA療法。 mRNA疫苗的成功進一步推動了對RNA研究的投資，促進了多種治療應用領域的快速創新和多元化發展。

對創新療法的需求不斷成長，正在推動市場成長：

對創新療法和快速疫苗研發能力日益成長的需求是RNA療法和疫苗市場的主要驅動力。慢性病盛行率上升、感染疾病爆發以及未被滿足的醫療需求，使得人們對開發速度比傳統生技藥品更快的靈活治療平台的需求日益強勁。生物技術研究投入的增加、政府的有利資助、不斷擴展的臨床研發管線以及RNA合成和遞送系統的持續技術進步，都在為RNA療法的商業化提供支持。這些因素正在顯著加速RNA療法和新一代疫苗在全球的應用。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 基於mRNA的療法
    • 基於siRNA的療法
    • 基於miRNA的療法
    • RNA干擾（RNAi）
    • 反義RNA
    • 其他
  • 市場規模及預測：依產品分類
    • RNA疫苗
    • RNA療法
    • RNA遞送系統
    • RNA合成服務
    • 其他
  • 市場規模及預測：依技術分類
    • 體外轉錄
    • 微陣列
    • RNA定序
    • RNA干擾技術
    • 其他
  • 市場規模及預測：依應用領域分類
    • 癌症
    • 感染疾病
    • 遺傳性疾病
    • 心血管疾病
    • 神經病變
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究機構
    • 受託研究機構（CRO）
    • 其他
  • 市場規模及預測：依製程分類
    • 臨床前階段
    • 臨床試驗
    • 商業化
    • 其他
  • 市場規模及預測：依組件分類
    • RNA分子
    • 快遞公司
    • 穩定器
    • 其他
  • 市場規模及預測：按解決方案分類
    • 藥物研發
    • 疫苗研發
    • 藥物輸送解決方案
    • 其他
  • 市場規模及預測：依階段分類
    • 發現
    • 臨床前開發
    • 臨床開發
    • 獲得監管機構的批准
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Moderna
  • BioNTech
  • CureVac
  • Arcturus Therapeutics
  • Translate Bio
  • Sarepta Therapeutics
  • Alnylam Pharmaceuticals
  • Ionis Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Silence Therapeutics
  • ProQR Therapeutics
  • Regulus Therapeutics
  • Marina Biotech
  • Arbutus Biopharma
  • Vir Biotechnology
  • Beam Therapeutics
  • Intellia Therapeutics
  • Editas Medicine
  • CRISPR Therapeutics

第9章 關於我們

簡介目錄
Product Code: GIS31566

The global RNA-Based Therapeutics and Vaccines Market is projected to grow from $0.3 billion in 2025 to $2.0 billion by 2035, at a compound annual growth rate (CAGR) of 24.6%. Growth is driven by advancements in biotechnology, increased prevalence of chronic diseases, and rising demand for personalized medicine, alongside regulatory support for innovative therapies. The RNA-Based Therapeutics and Vaccines Market is moderately consolidated, with mRNA vaccines leading the industry, followed by RNA interference therapeutics and antisense oligonucleotides. Demand is driven by applications in infectious diseases, oncology, and genetic disorders, supported by ongoing advancements in RNA science and delivery technologies. The competitive landscape includes established pharmaceutical companies alongside emerging biotechnology firms competing through innovation, product development, and pipeline expansion. Strategic collaborations, licensing agreements, mergers, and acquisitions remain common as companies strengthen research capabilities and broaden their portfolios. Partnerships between biotechnology companies, pharmaceutical manufacturers, and academic institutions continue to accelerate the development and commercialization of next-generation RNA-based therapeutics and vaccines.

Based on the Type segment, the RNA-Based Therapeutics and Vaccines market is segmented into mRNA-Based Therapeutics, siRNA-Based Therapeutics, miRNA-Based Therapeutics, RNA Interference (RNAi), Antisense RNA, and Others. Among these, mRNA-based therapeutics account for a significant share of the market due to their proven success in vaccine development, rapid design capabilities, and expanding applications in oncology and rare diseases. siRNA-based therapeutics are also witnessing strong growth, supported by increasing regulatory approvals and their ability to selectively silence disease-causing genes. Meanwhile, miRNA therapeutics, antisense RNA, and RNAi technologies continue to gain traction as research advances and clinical pipelines expand across multiple therapeutic areas.

Market Segmentation
TypemRNA-Based Therapeutics, siRNA-Based Therapeutics, miRNA-Based Therapeutics, RNA Interference (RNAi), Antisense RNA, Others
ProductRNA Vaccines, RNA Therapeutics, RNA Delivery Systems, RNA Synthesis Services, Others
TechnologyIn Vitro Transcription, Microarray, RNA Sequencing, RNA Interference Technology, Others
ComponentRNA Molecules, Delivery Carriers, Stabilizers, Others
ApplicationCancer, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases, Neurological Disorders, Others
ProcessPreclinical, Clinical Trials, Commercialization, Others
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations (CROs), Others
SolutionsTherapeutic Development, Vaccine Development, Drug Delivery Solutions, Others
StageDiscovery, Preclinical Development, Clinical Development, Regulatory Approval, Others

Based on the Application segment, the RNA-Based Therapeutics and Vaccines market is segmented into Cancer, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases, Neurological Disorders, and Others. Among these, infectious diseases represent a major application area, driven by the widespread adoption of mRNA vaccines and ongoing investments in pandemic preparedness. Cancer is another key segment, supported by the increasing development of personalized RNA-based immunotherapies and therapeutic vaccines. Additionally, the use of RNA technologies for treating genetic, cardiovascular, and neurological disorders is expanding as clinical research progresses and innovative RNA-based therapies demonstrate promising efficacy and safety in targeted disease management.

Geographical Overview

North America dominates the RNA-based therapeutics and vaccines market due to strong pharmaceutical innovation, extensive biotechnology research, and successful commercialization of mRNA technologies. Leading biotechnology companies, significant government funding, and robust clinical trial activity have accelerated product development. The region also benefits from advanced manufacturing capabilities, favorable regulatory support, and high healthcare expenditure. Increasing research into RNA therapeutics for oncology, rare diseases, and infectious diseases continues to expand market opportunities. Strong intellectual property protection and strategic partnerships further reinforce North America's leadership in this rapidly evolving therapeutic segment.

Asia-Pacific is anticipated to be the fastest-growing region in the RNA-based therapeutics and vaccines market owing to expanding biotechnology capabilities, rising investments in vaccine manufacturing, and increasing government support for advanced drug development. Countries such as China, Japan, South Korea, and India are strengthening research in RNA technologies through public-private collaborations. Growing demand for innovative therapies, expanding clinical research activities, and improving pharmaceutical manufacturing infrastructure are driving adoption. Rising healthcare expenditure and increasing focus on pandemic preparedness and precision medicine further contribute to strong regional market growth.

Key Trends and Drivers

Expansion of Advanced RNA Platforms Is Accelerating Therapeutic Innovation:

The increasing development of messenger RNA (mRNA), small interfering RNA (siRNA), and circular RNA platforms is a prominent trend in the RNA-based therapeutics and vaccines market. Advances in lipid nanoparticle delivery technologies and RNA stabilization techniques are improving therapeutic efficacy and expanding treatment possibilities beyond infectious diseases. Researchers are actively developing RNA-based therapies targeting oncology, rare diseases, cardiovascular disorders, and autoimmune conditions. The success of mRNA vaccines has accelerated broader investment in RNA research, supporting rapid innovation and diversification across multiple therapeutic applications.

Increasing Demand for Innovative Therapeutics Is Driving the Market Growth:

The growing demand for innovative treatment approaches and rapid vaccine development capabilities is a key driver of the RNA-based therapeutics and vaccines market. Increasing prevalence of chronic diseases, infectious outbreaks, and unmet medical needs has created strong demand for flexible therapeutic platforms capable of faster development compared to conventional biologics. Rising investments in biotechnology research, favorable government funding, expanding clinical pipelines, and continuous technological improvements in RNA synthesis and delivery systems are supporting commercialization. These factors are significantly accelerating the global adoption of RNA-based therapeutics and next-generation vaccines.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Solutions
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 mRNA-Based Therapeutics
    • 4.1.2 siRNA-Based Therapeutics
    • 4.1.3 miRNA-Based Therapeutics
    • 4.1.4 RNA Interference (RNAi)
    • 4.1.5 Antisense RNA
    • 4.1.6 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 RNA Vaccines
    • 4.2.2 RNA Therapeutics
    • 4.2.3 RNA Delivery Systems
    • 4.2.4 RNA Synthesis Services
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 In Vitro Transcription
    • 4.3.2 Microarray
    • 4.3.3 RNA Sequencing
    • 4.3.4 RNA Interference Technology
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Cancer
    • 4.4.2 Infectious Diseases
    • 4.4.3 Genetic Disorders
    • 4.4.4 Cardiovascular Diseases
    • 4.4.5 Neurological Disorders
    • 4.4.6 Others
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Pharmaceutical Companies
    • 4.5.2 Biotechnology Companies
    • 4.5.3 Research Institutes
    • 4.5.4 Contract Research Organizations (CROs)
    • 4.5.5 Others
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Preclinical
    • 4.6.2 Clinical Trials
    • 4.6.3 Commercialization
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 RNA Molecules
    • 4.7.2 Delivery Carriers
    • 4.7.3 Stabilizers
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Solutions (2020-2035)
    • 4.8.1 Therapeutic Development
    • 4.8.2 Vaccine Development
    • 4.8.3 Drug Delivery Solutions
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Discovery
    • 4.9.2 Preclinical Development
    • 4.9.3 Clinical Development
    • 4.9.4 Regulatory Approval
    • 4.9.5 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Component
      • 5.2.1.8 Solutions
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Component
      • 5.2.2.8 Solutions
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Component
      • 5.2.3.8 Solutions
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Component
      • 5.3.1.8 Solutions
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Component
      • 5.3.2.8 Solutions
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Component
      • 5.3.3.8 Solutions
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Component
      • 5.4.1.8 Solutions
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Component
      • 5.4.2.8 Solutions
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Component
      • 5.4.3.8 Solutions
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Component
      • 5.4.4.8 Solutions
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Component
      • 5.4.5.8 Solutions
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Component
      • 5.4.6.8 Solutions
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Component
      • 5.4.7.8 Solutions
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Component
      • 5.5.1.8 Solutions
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Component
      • 5.5.2.8 Solutions
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Component
      • 5.5.3.8 Solutions
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Component
      • 5.5.4.8 Solutions
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Component
      • 5.5.5.8 Solutions
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Component
      • 5.5.6.8 Solutions
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Component
      • 5.6.1.8 Solutions
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Component
      • 5.6.2.8 Solutions
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Component
      • 5.6.3.8 Solutions
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Component
      • 5.6.4.8 Solutions
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Component
      • 5.6.5.8 Solutions
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Moderna
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 BioNTech
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 CureVac
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Arcturus Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Translate Bio
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Sarepta Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Alnylam Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Ionis Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Arrowhead Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Dicerna Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Silence Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 ProQR Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Regulus Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Marina Biotech
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Arbutus Biopharma
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Vir Biotechnology
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Beam Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Intellia Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Editas Medicine
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 CRISPR Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us